MDS-O 200 mg Tablet 14's belongs to the group of anti-cancer medicines called demethylation agents indicated for continued treatment of acute myeloid leukaemia in adults who improved after chemotherapy but could not complete intensive curative therapy. Acute myeloid leukaemia is a type of cancer that forms in the blood-forming cells of the bone marrow.

MDS-O 200 mg Tablet 14's contains Azacitidine, which works by interfering with the growth of cancer cells, which are eventually destroyed by the body. It helps the bone marrow in the production of normal blood cells and kills abnormal cells in the bone marrow.
 
In some cases, MDS-O 200 mg Tablet 14's may cause side effects such as nausea, vomiting, diarrhoea, constipation, fatigue and abdominal pain. Most of these side effects may not require medical attention and resolve gradually over time. Do not be reluctant to talk with your doctor if any of the side effects persist or worsen.
 
Do not use MDS-O 200 mg Tablet 14's if you are pregnant or breastfeeding. Consult a doctor immediately if you become pregnant during treatment with MDS-O 200 mg Tablet 14's. This medicine is not recommended for children as safety and effectiveness have not been established. Inform your doctor about your health condition and medications to rule out any side effects/interactions.

MDS-O 200 mg Tablet 14's belongs to the group of anti-cancer medicines called demethylation agents indicated for continued treatment of adult patients with acute myeloid leukaemia who achieved first complete remission (all signs and symptoms of cancer have disappeared) or complete remission with incomplete blood count recovery following intensive induction chemotherapy and are not able to complete intensive curative therapy. MDS-O 200 mg Tablet 14's contains Azacitidine, a nucleoside metabolic inhibitor which works by interfering with the growth of cancer cells, which are eventually destroyed by the body. It helps the bone marrow in the production of normal blood cells and kills abnormal cells in the bone marrow.

• Nausea
• Vomiting
• Diarrhoea
• Constipation
• Dizziness
• Fatigue
• Abdominal pain
• Decreased appetite
• Arthralgia (joint pain)

Do not take MDS-O 200 mg Tablet 14's if you are allergic to any of its components or if you are breastfeeding. Inform the doctor if you have liver or kidney problems. Seek medical attention if you experience symptoms of neutropenia/low white blood cells (fever or chills, feeling very tired or weak, body aches, and unusual headache) or thrombocytopenia/low platelet count (unusual bleeding or bruising). Consult the doctor if you are pregnant, plan to become pregnant, or if you plan to father a child.

Drug-Drug Interactions: No interactions found/established.

Drug-Food Interactions: No interactions found/established.

Drug-Disease Interactions: No interactions found/established.

• Eat a healthy diet and exercise regularly as it helps maintain proper weight.
• Avoid smoking and alcohol consumption.
• Include vegetables and fruits in your diet.
• Avoid fast food, fried food, processed meats, refined carbs and added sugar.
• Get optimal sleep; rest well.
• Drink enough water and eat fibre-rich foods, vegetables and fruits.

• If you are a female, you should take a pregnancy test prior to the start of the treatment. Use reliable contraception to prevent pregnancy during treatment and for 6 months after the last dose.
• Male patients with partners of reproductive potential should use effective contraception during treatment and for 3 months after stopping the treatment.
• If the powder from the medicine comes in contact with your skin, wash the area well with soap and water immediately.
• If the powder from the medicine comes in contact with mucous membranes (eyes or mouth), flush the area with water immediately.

Acute myeloid leukaemia: Acute myeloid leukaemia, also called acute myelogenous leukaemia or acute nonlymphocytic leukaemia, is the cancer of blood and bone marrow with excess immature white blood cells. Symptoms include fever, recurrent infections, fatigue, and easy bruising.